Add BrightSurf on Google Email

Jewish General Hospital


First new C. difficile drug in a generation superior to existing treatments: Researchers

Researchers at the Jewish General Hospital and University of Calgary conducted a large-scale phase 3 trial showing Fidaxomicin significantly reduces CDI recurrence rates. The new antibiotic demonstrates improved cure rates compared to existing licensed treatment vancomycin, offering hope for patients struggling with recurrences.

SourceJewish General Hospital·JournalNew England Journal of Medicine·DateFeb 2, 2011